Dosing

ZENPEP offers the widest range of dosing options including the highest strength available—40,000 lipase units1

Flexible dosing may allow patients to minimize the number of capsules needed or get close to the calculated dose

May allow for customized dosing

May reduce the number of capsules needed

Gets your patient close to the calculated dose

Each ZENPEP capsule strength contains the specified amount of lipase, protease, and amylase1

Coverage for All Dosage Strengths

ZENPEP combined insurance coverage through commercial and Medicare Part D is 94%, with unrestricted access. Coverage is the same for all dosage strengths2

Data are not guarantee of coverage, or partial or full payment, by any payers listed. Actual benefits determined by respective plan adminstrator. Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient's coverage with applicable insurer. Allergan does not endorse any individual plans. Formulary coverage does not imply efficacy or safety.

 

ZENPEP Dosing Calculator

Calculate the ZENPEP dose in 3 easy steps!

Use the app below to calculate the per-meal ZENPEP dose for your patients with EPI due to cystic fibrosis or other conditions.

ZENPEP is not interchangeable with any other pancrelipase product. Therapy should be initiated at the lowest recommended dose and gradually increased. The dosage of ZENPEP should be individualized based on clinical symptoms, the degree of steatorrhea present, and the fat content of the diet. Dosing should not exceed the recommended maximum dosage set forth by the Cystic Fibrosis Foundation Consensus Conferences Guidelines.

Step 1: Patient Age

3,000

USP lipase units

per 120 mL of formula or per breastfeeding

Step 3: Recommended Lipase Units/kg Body Weight/Meal

USP Lipase Units
The dosage of ZENPEP should be individualized based on clinical symptoms, the degree of steatorrhea present, and the fat content of the diet.

Calculated Dose/Meal

10,000

USP lipase units

Step 3: Recommended Lipase Units/g Fat Ingested/Day

USP Lipase Units
The dosage of ZENPEP should be individualized based on clinical symptoms, the degree of steatorrhea present, and the fat content of the diet.

Calculated Dose/Meal

10,000

USP lipase units

It is recommended, unless clinically indicated, that enzyme doses should be less than 2,500 lipase units/kg of body weight per meal (or less than 10,000 lipase units/kg of body weight per day) or less than 4,000 lipase units/g of fat ingested per day.

Doses greater than 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day) should be used with caution and only if they are documented to be effective by 3-day fecal fat measures that indicate a significantly improved coefficient of fat absorption. Patients receiving higher doses than 6,000 lipase units/kg of body weight per meal should be examined and the dosage either immediately decreased or titrated downward to a lower range.

View Dosage Strengths

DISCLAIMER: By using this dosing calculator, you agree to the following: The dosing calculator is being provided "AS IS" and is intended for healthcare professional (HCP) use only. The dosing calculator is to be used only in conjunction with ZENPEP® (pancrelipase) delayed-release capsules. All calculations should be confirmed before use. The information being provided is not a substitute for clinical judgement. While the tool attempts to be as accurate as possible, it should not be relied upon as being comprehensive and error-free. Allergan, nor any party involved in the publication of this site, shall be liable to you or others for any decisions made or actions taken by you or others in reliance of this information. The user assumes all responsibility and risk for the use of this tool.

If you are not an HCP and have questions about ZENPEP dosing, please contact your HCP.

Dosage and Administration
  • ZENPEP is not interchangeable with any other pancrelipase product. Therapy should be initiated at the lowest recommended dose and gradually increased. The dosage of ZENPEP should be individualized based on clinical symptoms, the degree of steatorrhea present, and the fat content of the diet.
Infants (up to 12 months)
  • Infants may be given 3,000 lipase units (one capsule) per 120 mL of formula or per breastfeeding
  • Do not mix ZENPEP capsule contents directly into formula or breast milk prior to administration
Children Older than 12 Months and Younger than 4 Years
  • Enzyme dosing should begin with 1,000 lipase units/kg of body weight per meal to a maximum of 2,500 lipase units/kg of body weight per meal (or less than or equal to 10,000 lipase units/kg of body weight per day), or less than 4,000 lipase units/g fat ingested per day
Children 4 Years and Older and Adults
  • Enzyme dosing should begin with 500 lipase units/kg of body weight per meal to a maximum of 2,500 lipase units/kg of body weight per meal (or less than or equal to 10,000 lipase units/kg of body weight per day), or less than 4,000 lipase units/g fat ingested per day
  • Usually, half of the prescribed ZENPEP dose for an individualized full meal should be given with each snack. The total daily dose should reflect approximately three meals plus two or three snacks per day
Limitations on Dosing
  • Dosing should not exceed the recommended maximum dosage set forth by the Cystic Fibrosis Foundation Consensus Conferences Guidelines
Administration
  • ZENPEP should be swallowed whole. ZENPEP capsules and capsule contents should not be crushed or chewed
  • For infants or patients unable to swallow intact capsules, the contents may be sprinkled on small amounts of soft acidic food, eg, applesauce
  • For children and adults, ZENPEP should be taken during meals or snacks, with sufficient fluid

For complete information on dosage and administration, please see full Prescribing Information.

IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Fibrosing Colonopathy
  • Fibrosing colonopathy is a rare serious adverse reaction associated with high-dose use of pancreatic enzyme replacement.
  • Exercise caution when doses of ZENPEP exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day).
Potential for Irritation to Oral Mucosa
  • To avoid irritation of oral mucosa, care should be taken to ensure the ZENPEP capsule or its contents are not crushed, chewed, or retained in the mouth. ZENPEP may be added to a small amount of acidic soft food.
Potential for Risk of Hyperuricemia
  • Exercise caution when prescribing ZENPEP to patients with gout, renal impairment or hyperuricemia.
Potential Viral Exposure from the Product Source
  • There is theoretical risk of viral transmission with all pancreatic enzyme products, including ZENPEP; however, no cases of transmission of an infectious illness associated with the use of porcine pancreatic extracts have been reported.
Allergic Reactions
  • Rarely, severe allergic reactions including anaphylaxis, asthma, hives, and pruritus have been reported with other pancreatic enzyme products with different formulations of the same active ingredient (pancrelipase).
  • Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
 Adverse Reactions
  • The most common adverse events (≥6% of patients treated with ZENPEP) were abdominal pain, flatulence, headache, cough, decreased weight, early satiety, and contusion.
Additional Important Safety Information
  • ZENPEP is not interchangeable with any other pancrelipase product.
  • Dosing should not exceed the recommended maximum dosage set forth by the Cystic Fibrosis Foundation Consensus Conferences Guidelines.
INDICATIONS AND USAGE

ZENPEP® (pancrelipase) is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, or other conditions.

References

1. ZENPEP [package insert]. Irvine, CA: Allergan USA, Inc.; March 2017. 2. Data on file. Allergan Pharmaceuticals.

IMPORTANT SAFETY INFORMATION and INDICATION More Less
Warnings and Precautions
Fibrosing Colonopathy
  • Fibrosing colonopathy is a rare serious adverse reaction associated with high-dose use of pancreatic enzyme replacement.
  • Exercise caution when doses of ZENPEP exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day).
Potential for Irritation to Oral Mucosa
  • To avoid irritation of oral mucosa, care should be taken to ensure the ZENPEP capsule or its contents are not crushed, chewed, or retained in the mouth. ZENPEP may be added to a small amount of acidic soft food.
Potential for Risk of Hyperuricemia
  • Exercise caution when prescribing ZENPEP to patients with gout, renal impairment or hyperuricemia.
Potential Viral Exposure from the Product Source
  • There is theoretical risk of viral transmission with all pancreatic enzyme products, including ZENPEP; however, no cases of transmission of an infectious illness associated with the use of porcine pancreatic extracts have been reported.
Allergic Reactions
  • Rarely, severe allergic reactions including anaphylaxis, asthma, hives, and pruritus have been reported with other pancreatic enzyme products with different formulations of the same active ingredient (pancrelipase).
  • Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
 Adverse Reactions
  • The most common adverse events (≥6% of patients treated with ZENPEP) were abdominal pain, flatulence, headache, cough, decreased weight, early satiety, and contusion.
Additional Important Safety Information
  • ZENPEP is not interchangeable with any other pancrelipase product.
  • Dosing should not exceed the recommended maximum dosage set forth by the Cystic Fibrosis Foundation Consensus Conferences Guidelines.
INDICATIONS AND USAGE

ZENPEP® (pancrelipase) is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, or other conditions.